Interrogating Cancer Drivers via CRISPR – Webinar

Virtual Event On-Demand Webinar

Interrogating Cancer Drivers via CRISPR: Mutant TP53 as a Therapeutic Target in Hypodiploid B-cell Acute Lymphoblastic Leukemia

You are invited to a free webinar featuring Dr. Ernesto Diaz-Flores, a pediatric oncologist from the University of California at San Francisco. In this one hour telecast, Dr. Diaz-Flores will speak to the challenges and opportunities behind creating isogenic, hard-to-transduce hypodiploid cell lines using CRISPR technology as well as how to transduce primary cells. You will learn how to ensure high editing efficiency as well as how early selection of purified viable cells can greatly enhance downstream applications, including the generation of patient-derived xenografts.

In the last few years, interrogation of the role of altered genes in cancer has been greatly facilitated by the use of CRISPR/Cas. This gene-editing approach is a key research tool for modulating gene expression (knockout and knockin) efficiently and precisely. However, this approach can be limited depending on the cell type (hard-to-transduce, or primary cells). Such limitations are a challenging roadblock to advancing studies of a wide spectrum of malignant cells.

Patients with hypodiploid B-cell acute lymphoblastic leukemia (B-ALL) present with very poor prognosis (5-year event free survival <29%). These cells have been shown to exhibit mutations in p53 in >90% of cases (Diaz-Flores et al., Cancer Research, 2019). To better understand the mechanism of resistance that arises from p53 mutations, we wished to generate isogenic hypodiploid cell lines (including NALM-16) deficient in p53 and with knocking alleles of p53 wildtype or different mutant versions.

This seminar will cover the steps taken to go from 1%–2% lentiviral transduction efficiency to >95% in hard-to-transduce hypodiploid cell lines and primary cells. We will present how we were able to quickly and gently enrich transduced clones to allow such high transduction efficiency and the generation of knockouts for further studies.

AGBT 2022 Conference

AGBT Bonnet Creek, Orlando, FL

Visit https://levitasbio.com/agbt-2022/ for more details.

McDonnell Genome Institute, Washington University
Human Pangenome Reference Consortium (HPRC)

Valerie Schneider, Ph.D., National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health
“Navigating the changing human genome resource landscape: GRCh38, T2T-CHM13 and HPRC assemblies”

Arang Rhie, Ph.D., National Human Genome Research Institute, National Institutes of Health
“A finished Y chromosome from HG002 completes the T2T-CHM13 reference”

Xian Chang, UC Santa Cruz Genomics Institute
“The HPRC human pangenome graph: updates and applications”

British Association for Cancer Research (BACR)

NTU Events & Conferencing Nottingham

LevitasBio's disruptive solutions for cellular enrichment and characterization optimizes downstream workflows such as single cell sequencing, CRISPR workflows, cell line development, and more. Come by booth #3 to learn more.

PMWC – Precision Medicine World Conference

Santa Clara Convention Center Silicon Valley, CA

Join us at the upcoming conference where we will be showcasing our solutions in our booth and Innovation Showcase. Visit us in booth #D2818 to see our full portfolio, including the new LeviCell EOS System, a higher throughput solution that enables scalability up to 16x. Attend our presentation on Wednesday, June 29th from 9:30-10:00am, in Track 6, to hear the latest results and data that our technology can deliver.

Flow Cytometry UK

Edgbaston Park Hotel Birmingham

We look forward to meeting you at the upcoming Flow Cytometry UK!  In addition to the exhibit booth, our team will be hosting a commercial workshop where you can see our system in person.  Details below: Commercial Workshop: Wednesday, July 20 1515 - 1615 pm Elgar Suite Our on-site team:       James Williams  […]